arrow
Y

Yoshihisa Kodama

teine keijinkai hospital
H指数:21
被引数:2,285

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI - A Secondary Analysis of a Multicenter Randomized Controlled Trial

不可切除性肝细胞癌行选择性肝动脉化疗栓塞术后的肝功能变化:JIVROSG-2001 PRESIDENT-ALBI——一项多中心随机对照试验的二次分析

2025-12-010
OA
Prospective Multicenter Observational Study of Silent Brain Infarction Following Transradial Hepatic Intervention (The MOSAIC Study)

前瞻性多中心观察性研究:经桡动脉肝干预后的静息性脑梗死(MOSAIC研究)

2025-08-060
OAAI
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
2025-03-110
OAAI
Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria

REPLACEMENT研究的最终分析:一项关于阿替利珠单抗联合贝伐珠单抗(atezo plus bev)治疗经肝动脉化疗栓塞(TACE)不适宜的超出“七例标准”的中期肝细胞癌(HCC)患者的II期研究

2024-12-011
PRE
IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
2023-11-012
PRE
Fat Distribution Patterns and Future Type 2 Diabetes
2022-06-2030
OA
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302
2022-06-1537
OAAI